Lonza Group AG (LONN) - Total Assets
Based on the latest financial reports, Lonza Group AG (LONN) holds total assets worth CHF18.97 Billion CHF (≈ $23.98 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of Lonza Group AG to assess the company's total reinvestment commitment from operating cash flow.
Lonza Group AG - Total Assets Trend (2004–2025)
This chart illustrates how Lonza Group AG's total assets have evolved over time, based on quarterly financial data. Explore LONN long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Lonza Group AG - Asset Composition Analysis
Current Asset Composition (December 2025)
Lonza Group AG's total assets of CHF18.97 Billion consist of 42.2% current assets and 57.8% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF481.00 Million | 3.8% |
| Accounts Receivable | CHF1.78 Billion | 9.4% |
| Inventory | CHF1.68 Billion | 8.9% |
| Property, Plant & Equipment | CHF8.30 Billion | 43.8% |
| Intangible Assets | CHF329.00 Million | 1.7% |
| Goodwill | CHF1.96 Billion | 10.3% |
Asset Composition Trend (2004–2025)
This chart illustrates how Lonza Group AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see LONN market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lonza Group AG's current assets represent 42.2% of total assets in 2025, an increase from 35.5% in 2004.
- Cash Position: Cash and equivalents constituted 3.8% of total assets in 2025, up from 1.2% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 2.0% in 2004.
- Asset Diversification: The largest asset category is property, plant & equipment at 43.8% of total assets.
Lonza Group AG Competitors by Total Assets
Key competitors of Lonza Group AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
RHYTHM Biosciences Ltd
AU:RHY
|
Australia | AU$3.10 Million |
|
Genetic Signatures Ltd
AU:GSS
|
Australia | AU$49.04 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Cryosite Ltd
AU:CTE
|
Australia | AU$26.55 Million |
|
Inoviq Ltd
AU:IIQ
|
Australia | AU$24.52 Million |
Lonza Group AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.24 | 1.52 | 1.55 |
| Quick Ratio | 1.77 | 1.04 | 1.18 |
| Cash Ratio | 0.00 | 0.00 | 0.16 |
| Working Capital | CHF4.43 Billion | CHF1.86 Billion | CHF1.69 Billion |
Lonza Group AG - Advanced Valuation Insights
This section examines the relationship between Lonza Group AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.26 |
| Latest Market Cap to Assets Ratio | 1.78 |
| Asset Growth Rate (YoY) | -3.9% |
| Total Assets | CHF18.97 Billion |
| Market Capitalization | $33.73 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Lonza Group AG's assets above their book value (1.78x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: Lonza Group AG's assets decreased by 3.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Lonza Group AG (2004–2025)
The table below shows the annual total assets of Lonza Group AG from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CHF18.97 Billion ≈ $23.98 Billion |
-3.88% |
| 2024-12-31 | CHF19.73 Billion ≈ $24.95 Billion |
+17.12% |
| 2023-12-31 | CHF16.85 Billion ≈ $21.30 Billion |
-2.93% |
| 2022-12-31 | CHF17.36 Billion ≈ $21.94 Billion |
+5.45% |
| 2021-12-31 | CHF16.46 Billion ≈ $20.81 Billion |
+12.54% |
| 2020-12-31 | CHF14.62 Billion ≈ $18.49 Billion |
+5.66% |
| 2019-12-31 | CHF13.84 Billion ≈ $17.50 Billion |
-0.57% |
| 2018-12-31 | CHF13.92 Billion ≈ $17.60 Billion |
+0.65% |
| 2017-12-31 | CHF13.83 Billion ≈ $17.49 Billion |
+102.56% |
| 2016-12-31 | CHF6.83 Billion ≈ $8.63 Billion |
+9.28% |
| 2015-12-31 | CHF6.25 Billion ≈ $7.90 Billion |
-3.00% |
| 2014-12-31 | CHF6.44 Billion ≈ $8.14 Billion |
+1.07% |
| 2013-12-31 | CHF6.37 Billion ≈ $8.06 Billion |
-10.24% |
| 2012-12-31 | CHF7.10 Billion ≈ $8.98 Billion |
+1.14% |
| 2011-12-31 | CHF7.02 Billion ≈ $8.88 Billion |
+46.92% |
| 2010-12-31 | CHF4.78 Billion ≈ $6.04 Billion |
-3.36% |
| 2009-12-31 | CHF4.94 Billion ≈ $6.25 Billion |
+0.24% |
| 2008-12-31 | CHF4.93 Billion ≈ $6.24 Billion |
-0.38% |
| 2007-12-31 | CHF4.95 Billion ≈ $6.26 Billion |
+26.56% |
| 2006-12-31 | CHF3.91 Billion ≈ $4.95 Billion |
-9.67% |
| 2005-12-31 | CHF4.33 Billion ≈ $5.48 Billion |
+29.63% |
| 2004-12-31 | CHF3.34 Billion ≈ $4.22 Billion |
-- |
About Lonza Group AG
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biol… Read more